Overview

Cisplatin in Castration Resistant Prostate Cancer

Status:
Recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
It is hypothesized that treatment with cisplatin will reverse emerging refractoriness to enzalutimide in patients with CRPC by affecting AR function.
Phase:
Early Phase 1
Details
Lead Sponsor:
University of Rochester
Collaborator:
Roswell Park Cancer Institute
Treatments:
Cisplatin